English

Aptose Biosciences Inc.

EDGAR

APTO Quarterly report (10-Q) · filed 2026-05-13

361 filing records in this dataset, filed from 2005-11-10 to 2026-05-13. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Cash and cash equivalents: 935 thousand USD 2025-12-31 Source
Exact value

935000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 2.55 million shares 2026-03-31 Source
Exact value

2552429 shares

Reported share-count change

0.00% · 0 shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

2552429 shares · 2025-03-31· Source
2552429 shares · 2026-03-31· Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-05-13.

Financial data available through: 2025-12-31.

Coverage by financial measure

revenue: No compatible figures in this window
operating income: No compatible figures in this window
Net income: 6 of 11 periods available· newest 2025-12-31
Operating cash flow: 6 of 11 periods available· newest 2025-12-31
Capital expenditure: 6 of 11 periods available· newest 2025-12-31
Total assets: 6 of 11 periods available· newest 2025-12-31
Total liabilities: 6 of 11 periods available· newest 2025-12-31
Current assets: 6 of 11 periods available· newest 2025-12-31
Current liabilities: 6 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 6 of 11 periods available· newest 2025-12-31
long term debt: No compatible figures in this window
Shares outstanding: 6 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Net income
−USD 38,000

Prior period

−USD 25.43 million

2024-01-01 – 2024-12-31
Current period

−USD 25.47 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-25468000 − -25430000 = -38000 USD

-25430000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-25468000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Aptose Biosciences Inc. · 2025-12-31 Aptose Biosciences Inc. (edgar:882361) Year-over-year change in Net income: -38000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T21:34:55Z Snapshot: 9b84e70cefe2efe4357ab2d9b1cc658ccd98714ca9ba5d6ee57309b4d56e0c9d Dimensions: Consolidated View: https://fundies.io/companies/edgar/882361?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -25468000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/882361/000119312526135012/none-20251231.htm#3692393 Filing: 000119312526135012 Input fundies:NetIncome: -25430000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/882361/000119312526135012/none-20251231.htm#3694212 Filing: 000119312526135012
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 13.99 million

Prior period

−USD 35.98 million

2024-01-01 – 2024-12-31
Current period

−USD 21.99 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-21990000 − -35977000 = 13987000 USD

-35977000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-21990000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Aptose Biosciences Inc. · 2025-12-31 Aptose Biosciences Inc. (edgar:882361) Year-over-year change in Operating cash flow: 13987000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T21:34:55Z Snapshot: 9b84e70cefe2efe4357ab2d9b1cc658ccd98714ca9ba5d6ee57309b4d56e0c9d Dimensions: Consolidated View: https://fundies.io/companies/edgar/882361?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -21990000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/882361/000119312526135012/none-20251231.htm#2555973 Filing: 000119312526135012 Input fundies:OperatingCashFlow: -35977000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/882361/000119312526135012/none-20251231.htm#2557900 Filing: 000119312526135012
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-100%

Prior period

USD 5,000

2024-01-01 – 2024-12-31
Current period

USD 0

2025-01-01 – 2025-12-31

Exact inputs and evidence

0 − 5000 = -5000 USD

5000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
0 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Aptose Biosciences Inc. · 2025-12-31 Aptose Biosciences Inc. (edgar:882361) Year-over-year change in Capital expenditure: -5000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T21:34:55Z Snapshot: 9b84e70cefe2efe4357ab2d9b1cc658ccd98714ca9ba5d6ee57309b4d56e0c9d Dimensions: Consolidated View: https://fundies.io/companies/edgar/882361?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 0 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/882361/000119312526135012/none-20251231.htm#2566880 Filing: 000119312526135012 Input fundies:CapitalExpenditure: 5000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/882361/000119312526135012/none-20251231.htm#2568785 Filing: 000119312526135012
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Revenue.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

Revenue is not reported for this company, so its costs cannot be shown as a share of it.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

Not enough comparable data to show this history.

Values and sources

Revenue values and source evidence
Period	Series	Value	Source evidence

Revenue growth

Change in revenue from the same financial period one year earlier.

Not enough comparable data to show this history.

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Not enough comparable data to show this history.

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence

Operating cash flow

Cash generated by the company’s normal business operations.

Not enough comparable data to show this history.

Values and sources

Operating cash flow values and source evidence
Period	Series	Value	Source evidence

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

Not enough comparable data to show this history.

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

Not enough comparable data to show this history.

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence

Current assets to current liabilities

Current assets divided by current liabilities.

Not enough comparable data to show this history.

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2020 2020-01-01 – 2020-12-31	−USD 55.24 million Exact value Exact value: -55238000 USD 2020-01-01 – 2020-12-31: -55238000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Aptose Biosciences Inc. · 2020-12-31 Aptose Biosciences Inc. (edgar:882361) Net Income: -55238000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T21:34:55Z Snapshot: 9b84e70cefe2efe4357ab2d9b1cc658ccd98714ca9ba5d6ee57309b4d56e0c9d Dimensions: Consolidated View: https://fundies.io/companies/edgar/882361/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -55238000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/882361/000117184322002048/apto20211231_10k.htm#1398407 Filing: 000117184322002048 The citation records this snapshot. The page link may show a newer release later.	−USD 33.89 million Exact value Exact value: -33891000 USD 2020-01-01 – 2020-12-31: -33891000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Aptose Biosciences Inc. · 2020-12-31 Aptose Biosciences Inc. (edgar:882361) Operating Cash Flow: -33891000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T21:34:55Z Snapshot: 9b84e70cefe2efe4357ab2d9b1cc658ccd98714ca9ba5d6ee57309b4d56e0c9d Dimensions: Consolidated View: https://fundies.io/companies/edgar/882361/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -33891000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/882361/000117184322002048/apto20211231_10k.htm#919028 Filing: 000117184322002048 The citation records this snapshot. The page link may show a newer release later.	USD 79,000 Exact value Exact value: 79000 USD 2020-01-01 – 2020-12-31: 79000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Aptose Biosciences Inc. · 2020-12-31 Aptose Biosciences Inc. (edgar:882361) Capital Expenditure: 79000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T21:34:55Z Snapshot: 9b84e70cefe2efe4357ab2d9b1cc658ccd98714ca9ba5d6ee57309b4d56e0c9d Dimensions: Consolidated View: https://fundies.io/companies/edgar/882361/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 79000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/882361/000117184322002048/apto20211231_10k.htm#932841 Filing: 000117184322002048 The citation records this snapshot. The page link may show a newer release later.	−USD 33.97 million Calculation and evidence -33891000 − 79000 USD Exact free cash flow: -33970000 USD 2020-01-01 – 2020-12-31: -33891000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 79000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Aptose Biosciences Inc. · 2020-12-31 Aptose Biosciences Inc. (edgar:882361) Free cash flow: -33970000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T21:34:55Z Snapshot: 9b84e70cefe2efe4357ab2d9b1cc658ccd98714ca9ba5d6ee57309b4d56e0c9d Dimensions: Consolidated View: https://fundies.io/companies/edgar/882361?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -33891000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/882361/000117184322002048/apto20211231_10k.htm#919028 Filing: 000117184322002048 Input fundies:CapitalExpenditure: 79000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/882361/000117184322002048/apto20211231_10k.htm#932841 Filing: 000117184322002048 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 65.35 million Exact value Exact value: -65354000 USD 2021-01-01 – 2021-12-31: -65354000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Aptose Biosciences Inc. · 2021-12-31 Aptose Biosciences Inc. (edgar:882361) Net Income: -65354000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T21:34:55Z Snapshot: 9b84e70cefe2efe4357ab2d9b1cc658ccd98714ca9ba5d6ee57309b4d56e0c9d Dimensions: Consolidated View: https://fundies.io/companies/edgar/882361/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -65354000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/882361/000095017023009560/apto-20221231.htm#2517701 Filing: 000095017023009560 The citation records this snapshot. The page link may show a newer release later.	−USD 43.3 million Exact value Exact value: -43304000 USD 2021-01-01 – 2021-12-31: -43304000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Aptose Biosciences Inc. · 2021-12-31 Aptose Biosciences Inc. (edgar:882361) Operating Cash Flow: -43304000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T21:34:55Z Snapshot: 9b84e70cefe2efe4357ab2d9b1cc658ccd98714ca9ba5d6ee57309b4d56e0c9d Dimensions: Consolidated View: https://fundies.io/companies/edgar/882361/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -43304000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/882361/000095017023009560/apto-20221231.htm#1598186 Filing: 000095017023009560 The citation records this snapshot. The page link may show a newer release later.	USD 212,000 Exact value Exact value: 212000 USD 2021-01-01 – 2021-12-31: 212000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Aptose Biosciences Inc. · 2021-12-31 Aptose Biosciences Inc. (edgar:882361) Capital Expenditure: 212000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T21:34:55Z Snapshot: 9b84e70cefe2efe4357ab2d9b1cc658ccd98714ca9ba5d6ee57309b4d56e0c9d Dimensions: Consolidated View: https://fundies.io/companies/edgar/882361/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 212000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/882361/000095017023009560/apto-20221231.htm#1632235 Filing: 000095017023009560 The citation records this snapshot. The page link may show a newer release later.	−USD 43.52 million Calculation and evidence -43304000 − 212000 USD Exact free cash flow: -43516000 USD 2021-01-01 – 2021-12-31: -43304000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 212000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Aptose Biosciences Inc. · 2021-12-31 Aptose Biosciences Inc. (edgar:882361) Free cash flow: -43516000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T21:34:55Z Snapshot: 9b84e70cefe2efe4357ab2d9b1cc658ccd98714ca9ba5d6ee57309b4d56e0c9d Dimensions: Consolidated View: https://fundies.io/companies/edgar/882361?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -43304000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/882361/000095017023009560/apto-20221231.htm#1598186 Filing: 000095017023009560 Input fundies:CapitalExpenditure: 212000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/882361/000095017023009560/apto-20221231.htm#1632235 Filing: 000095017023009560 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 41.82 million Exact value Exact value: -41823000 USD 2022-01-01 – 2022-12-31: -41823000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Aptose Biosciences Inc. · 2022-12-31 Aptose Biosciences Inc. (edgar:882361) Net Income: -41823000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T21:34:55Z Snapshot: 9b84e70cefe2efe4357ab2d9b1cc658ccd98714ca9ba5d6ee57309b4d56e0c9d Dimensions: Consolidated View: https://fundies.io/companies/edgar/882361/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -41823000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/882361/000095017024036537/apto-20231231.htm#1921901 Filing: 000095017024036537 The citation records this snapshot. The page link may show a newer release later.	−USD 32.32 million Exact value Exact value: -32322000 USD 2022-01-01 – 2022-12-31: -32322000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Aptose Biosciences Inc. · 2022-12-31 Aptose Biosciences Inc. (edgar:882361) Operating Cash Flow: -32322000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T21:34:55Z Snapshot: 9b84e70cefe2efe4357ab2d9b1cc658ccd98714ca9ba5d6ee57309b4d56e0c9d Dimensions: Consolidated View: https://fundies.io/companies/edgar/882361/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -32322000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/882361/000095017024036537/apto-20231231.htm#1267370 Filing: 000095017024036537 The citation records this snapshot. The page link may show a newer release later.	USD 24,000 Exact value Exact value: 24000 USD 2022-01-01 – 2022-12-31: 24000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Aptose Biosciences Inc. · 2022-12-31 Aptose Biosciences Inc. (edgar:882361) Capital Expenditure: 24000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T21:34:55Z Snapshot: 9b84e70cefe2efe4357ab2d9b1cc658ccd98714ca9ba5d6ee57309b4d56e0c9d Dimensions: Consolidated View: https://fundies.io/companies/edgar/882361/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 24000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/882361/000095017024036537/apto-20231231.htm#1297153 Filing: 000095017024036537 The citation records this snapshot. The page link may show a newer release later.	−USD 32.35 million Calculation and evidence -32322000 − 24000 USD Exact free cash flow: -32346000 USD 2022-01-01 – 2022-12-31: -32322000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 24000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Aptose Biosciences Inc. · 2022-12-31 Aptose Biosciences Inc. (edgar:882361) Free cash flow: -32346000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T21:34:55Z Snapshot: 9b84e70cefe2efe4357ab2d9b1cc658ccd98714ca9ba5d6ee57309b4d56e0c9d Dimensions: Consolidated View: https://fundies.io/companies/edgar/882361?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -32322000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/882361/000095017024036537/apto-20231231.htm#1267370 Filing: 000095017024036537 Input fundies:CapitalExpenditure: 24000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/882361/000095017024036537/apto-20231231.htm#1297153 Filing: 000095017024036537 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 51.21 million Exact value Exact value: -51207000 USD 2023-01-01 – 2023-12-31: -51207000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Aptose Biosciences Inc. · 2023-12-31 Aptose Biosciences Inc. (edgar:882361) Net Income: -51207000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T21:34:55Z Snapshot: 9b84e70cefe2efe4357ab2d9b1cc658ccd98714ca9ba5d6ee57309b4d56e0c9d Dimensions: Consolidated View: https://fundies.io/companies/edgar/882361/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -51207000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/882361/000095017025046366/apto-20241231.htm#3268958 Filing: 000095017025046366 The citation records this snapshot. The page link may show a newer release later.	−USD 44.59 million Exact value Exact value: -44590000 USD 2023-01-01 – 2023-12-31: -44590000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Aptose Biosciences Inc. · 2023-12-31 Aptose Biosciences Inc. (edgar:882361) Operating Cash Flow: -44590000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T21:34:55Z Snapshot: 9b84e70cefe2efe4357ab2d9b1cc658ccd98714ca9ba5d6ee57309b4d56e0c9d Dimensions: Consolidated View: https://fundies.io/companies/edgar/882361/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -44590000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/882361/000095017025046366/apto-20241231.htm#2253787 Filing: 000095017025046366 The citation records this snapshot. The page link may show a newer release later.	USD 29,000 Exact value Exact value: 29000 USD 2023-01-01 – 2023-12-31: 29000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Aptose Biosciences Inc. · 2023-12-31 Aptose Biosciences Inc. (edgar:882361) Capital Expenditure: 29000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T21:34:55Z Snapshot: 9b84e70cefe2efe4357ab2d9b1cc658ccd98714ca9ba5d6ee57309b4d56e0c9d Dimensions: Consolidated View: https://fundies.io/companies/edgar/882361/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 29000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/882361/000095017025046366/apto-20241231.htm#2305301 Filing: 000095017025046366 The citation records this snapshot. The page link may show a newer release later.	−USD 44.62 million Calculation and evidence -44590000 − 29000 USD Exact free cash flow: -44619000 USD 2023-01-01 – 2023-12-31: -44590000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 29000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Aptose Biosciences Inc. · 2023-12-31 Aptose Biosciences Inc. (edgar:882361) Free cash flow: -44619000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T21:34:55Z Snapshot: 9b84e70cefe2efe4357ab2d9b1cc658ccd98714ca9ba5d6ee57309b4d56e0c9d Dimensions: Consolidated View: https://fundies.io/companies/edgar/882361?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -44590000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/882361/000095017025046366/apto-20241231.htm#2253787 Filing: 000095017025046366 Input fundies:CapitalExpenditure: 29000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/882361/000095017025046366/apto-20241231.htm#2305301 Filing: 000095017025046366 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 25.43 million Exact value Exact value: -25430000 USD 2024-01-01 – 2024-12-31: -25430000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Aptose Biosciences Inc. · 2024-12-31 Aptose Biosciences Inc. (edgar:882361) Net Income: -25430000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T21:34:55Z Snapshot: 9b84e70cefe2efe4357ab2d9b1cc658ccd98714ca9ba5d6ee57309b4d56e0c9d Dimensions: Consolidated View: https://fundies.io/companies/edgar/882361/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -25430000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/882361/000119312526135012/none-20251231.htm#3694212 Filing: 000119312526135012 The citation records this snapshot. The page link may show a newer release later.	−USD 35.98 million Exact value Exact value: -35977000 USD 2024-01-01 – 2024-12-31: -35977000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Aptose Biosciences Inc. · 2024-12-31 Aptose Biosciences Inc. (edgar:882361) Operating Cash Flow: -35977000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T21:34:55Z Snapshot: 9b84e70cefe2efe4357ab2d9b1cc658ccd98714ca9ba5d6ee57309b4d56e0c9d Dimensions: Consolidated View: https://fundies.io/companies/edgar/882361/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -35977000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/882361/000119312526135012/none-20251231.htm#2557900 Filing: 000119312526135012 The citation records this snapshot. The page link may show a newer release later.	USD 5,000 Exact value Exact value: 5000 USD 2024-01-01 – 2024-12-31: 5000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Aptose Biosciences Inc. · 2024-12-31 Aptose Biosciences Inc. (edgar:882361) Capital Expenditure: 5000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T21:34:55Z Snapshot: 9b84e70cefe2efe4357ab2d9b1cc658ccd98714ca9ba5d6ee57309b4d56e0c9d Dimensions: Consolidated View: https://fundies.io/companies/edgar/882361/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 5000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/882361/000119312526135012/none-20251231.htm#2568785 Filing: 000119312526135012 The citation records this snapshot. The page link may show a newer release later.	−USD 35.98 million Calculation and evidence -35977000 − 5000 USD Exact free cash flow: -35982000 USD 2024-01-01 – 2024-12-31: -35977000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 5000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Aptose Biosciences Inc. · 2024-12-31 Aptose Biosciences Inc. (edgar:882361) Free cash flow: -35982000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T21:34:55Z Snapshot: 9b84e70cefe2efe4357ab2d9b1cc658ccd98714ca9ba5d6ee57309b4d56e0c9d Dimensions: Consolidated View: https://fundies.io/companies/edgar/882361?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -35977000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/882361/000119312526135012/none-20251231.htm#2557900 Filing: 000119312526135012 Input fundies:CapitalExpenditure: 5000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/882361/000119312526135012/none-20251231.htm#2568785 Filing: 000119312526135012 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 25.47 million Exact value Exact value: -25468000 USD 2025-01-01 – 2025-12-31: -25468000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Aptose Biosciences Inc. · 2025-12-31 Aptose Biosciences Inc. (edgar:882361) Net Income: -25468000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T21:34:55Z Snapshot: 9b84e70cefe2efe4357ab2d9b1cc658ccd98714ca9ba5d6ee57309b4d56e0c9d Dimensions: Consolidated View: https://fundies.io/companies/edgar/882361/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -25468000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/882361/000119312526135012/none-20251231.htm#3692393 Filing: 000119312526135012 The citation records this snapshot. The page link may show a newer release later.	−USD 21.99 million Exact value Exact value: -21990000 USD 2025-01-01 – 2025-12-31: -21990000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Aptose Biosciences Inc. · 2025-12-31 Aptose Biosciences Inc. (edgar:882361) Operating Cash Flow: -21990000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T21:34:55Z Snapshot: 9b84e70cefe2efe4357ab2d9b1cc658ccd98714ca9ba5d6ee57309b4d56e0c9d Dimensions: Consolidated View: https://fundies.io/companies/edgar/882361/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -21990000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/882361/000119312526135012/none-20251231.htm#2555973 Filing: 000119312526135012 The citation records this snapshot. The page link may show a newer release later.	USD 0 Exact value Exact value: 0 USD 2025-01-01 – 2025-12-31: 0 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Aptose Biosciences Inc. · 2025-12-31 Aptose Biosciences Inc. (edgar:882361) Capital Expenditure: 0 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T21:34:55Z Snapshot: 9b84e70cefe2efe4357ab2d9b1cc658ccd98714ca9ba5d6ee57309b4d56e0c9d Dimensions: Consolidated View: https://fundies.io/companies/edgar/882361/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 0 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/882361/000119312526135012/none-20251231.htm#2566880 Filing: 000119312526135012 The citation records this snapshot. The page link may show a newer release later.	−USD 21.99 million Calculation and evidence -21990000 − 0 USD Exact free cash flow: -21990000 USD 2025-01-01 – 2025-12-31: -21990000 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 0 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Aptose Biosciences Inc. · 2025-12-31 Aptose Biosciences Inc. (edgar:882361) Free cash flow: -21990000 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T21:34:55Z Snapshot: 9b84e70cefe2efe4357ab2d9b1cc658ccd98714ca9ba5d6ee57309b4d56e0c9d Dimensions: Consolidated View: https://fundies.io/companies/edgar/882361?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -21990000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/882361/000119312526135012/none-20251231.htm#2555973 Filing: 000119312526135012 Input fundies:CapitalExpenditure: 0 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/882361/000119312526135012/none-20251231.htm#2566880 Filing: 000119312526135012 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

361 filings · 2,359 latest values · 2,359 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0000882361, 882361, APTO, apto, edgar:882361

Also known as APTOSE BIOSCIENCES INC., Aptose Biosciences Inc., Aptose Biosciences Inc., (formerly LORUS THERAPEUTICS INC.), IMUTEC PHARMA INC, LORUS THERAPEUTICS INC

Aptose Biosciences Inc.

Reported share-count change

Company performance

What changed year over year

Net income

Operating cash flow

Capital expenditure

Where revenue goes

Growth

Profit and cash

Balance sheet

Cash generation